Patient characteristics
| . | GVHD patients . | HCT recipients undergoing serial skin biopsies . | |||
|---|---|---|---|---|---|
| aGVHD (n = 25) . | clGVHD (n = 17) . | csGVHD (n = 7) . | no aGVHD (n = 7) . | aGVHD (n = 7) . | |
| Mean age, y + SD | 46.4 ± 13.0 | 44.7 ± 12.6 | 52.0 ± 8.0 | 49.0 ± 6.7 | 46.7 ± 11 |
| Gender recipient | |||||
| Female | 13 | 10 | 4 | 5 | 5 |
| Male | 12 | 7 | 3 | 2 | 2 |
| Diagnosis prior to HCT | |||||
| AML | 10 | 6 | 2 | 1 | 1 |
| CML | 1 | 2 | 1 | ||
| HL | 1 | ||||
| NHL | 5 | 2 | 1 | 1 | 1 |
| sAML | 3 | 2 | |||
| ALL | 3 | 6 | 1 | 2 | 2 |
| MDS | 2 | 1 | 1 | ||
| CLL | 1 | ||||
| PNH | 1 | ||||
| Disease stage prior to HCT | |||||
| CR1 | 8 | 5 | 3 | 4 | 4 |
| CR2 | 7 | 3 | 1 | ||
| CR3 | 1 | 1 | 3 | ||
| CR4 | 1 | ||||
| CR5 | 1 | ||||
| PROG | 1 | 1 | 1 | ||
| REFR | 7 | 5 | 4 | 1 | |
| CP | 1 | ||||
| Stem cell source | |||||
| BM | 2 | 1 | 2 | 1 | |
| PBSC | 23 | 17 | 6 | 5 | 6 |
| Donor type | |||||
| MUD | 15 | 8 | 5 | 2 | 2 |
| MMUD | 6 | 5 | 2 | 2 | |
| SIB | 4 | 4 | 2 | 3 | 3 |
| Gender mismatch (donor/recipient) | |||||
| F/F | 11 | 2 | 2 | 4 | 3 |
| M/F | 2 | 8 | 1 | 1 | 2 |
| M/M | 12 | 4 | 1 | 1 | 2 |
| F/M | 3 | 1 | 1 | ||
| N/A | 2 | ||||
| Conditioning | |||||
| MAC | 2 | ||||
| MAC (TBI) | 9 | 8 | 6 | 3 | 2 |
| RIC | 8 | 6 | 2 | ||
| RIC (TBI) | 6 | 3 | 1 | 2 | 5 |
| GVHD prophylaxis | |||||
| CSA | 1 | 1 | 1 | 1 | |
| CSA MMF | 13 | 6 | 3 | 2 | |
| CSA MTX | 11 | 10 | 6 | 4 | 4 |
| GVHD score skin | (modified Glucksberg criteria35 ) | (NIH consensus criteria3 ) | (NIH consensus criteria3 ) | ||
| Score 1 | 6 | 4 | |||
| Score 2 | 7 | 7 | 1 | ||
| Score 3 | 12 | 6 | 6 | ||
| GVHD overall grade | (modified Glucksberg criteria35 ) | (NIH consensus criteria3 ) | (NIH consensus criteria3 ) | ||
| Grade 1 | 10 | ||||
| Grade 2 | 10 | ||||
| Grade 3 | 2 | ||||
| Grade 4 | 3 | ||||
| Mild | 2 | ||||
| Moderate | 9 | 1 | |||
| Severe | 6 | 6 | |||
| Onset type of cGVHD | |||||
| DN | 4 | 2 | |||
| QUIESC | 9 | 5 | |||
| PROG | 4 | ||||
| . | GVHD patients . | HCT recipients undergoing serial skin biopsies . | |||
|---|---|---|---|---|---|
| aGVHD (n = 25) . | clGVHD (n = 17) . | csGVHD (n = 7) . | no aGVHD (n = 7) . | aGVHD (n = 7) . | |
| Mean age, y + SD | 46.4 ± 13.0 | 44.7 ± 12.6 | 52.0 ± 8.0 | 49.0 ± 6.7 | 46.7 ± 11 |
| Gender recipient | |||||
| Female | 13 | 10 | 4 | 5 | 5 |
| Male | 12 | 7 | 3 | 2 | 2 |
| Diagnosis prior to HCT | |||||
| AML | 10 | 6 | 2 | 1 | 1 |
| CML | 1 | 2 | 1 | ||
| HL | 1 | ||||
| NHL | 5 | 2 | 1 | 1 | 1 |
| sAML | 3 | 2 | |||
| ALL | 3 | 6 | 1 | 2 | 2 |
| MDS | 2 | 1 | 1 | ||
| CLL | 1 | ||||
| PNH | 1 | ||||
| Disease stage prior to HCT | |||||
| CR1 | 8 | 5 | 3 | 4 | 4 |
| CR2 | 7 | 3 | 1 | ||
| CR3 | 1 | 1 | 3 | ||
| CR4 | 1 | ||||
| CR5 | 1 | ||||
| PROG | 1 | 1 | 1 | ||
| REFR | 7 | 5 | 4 | 1 | |
| CP | 1 | ||||
| Stem cell source | |||||
| BM | 2 | 1 | 2 | 1 | |
| PBSC | 23 | 17 | 6 | 5 | 6 |
| Donor type | |||||
| MUD | 15 | 8 | 5 | 2 | 2 |
| MMUD | 6 | 5 | 2 | 2 | |
| SIB | 4 | 4 | 2 | 3 | 3 |
| Gender mismatch (donor/recipient) | |||||
| F/F | 11 | 2 | 2 | 4 | 3 |
| M/F | 2 | 8 | 1 | 1 | 2 |
| M/M | 12 | 4 | 1 | 1 | 2 |
| F/M | 3 | 1 | 1 | ||
| N/A | 2 | ||||
| Conditioning | |||||
| MAC | 2 | ||||
| MAC (TBI) | 9 | 8 | 6 | 3 | 2 |
| RIC | 8 | 6 | 2 | ||
| RIC (TBI) | 6 | 3 | 1 | 2 | 5 |
| GVHD prophylaxis | |||||
| CSA | 1 | 1 | 1 | 1 | |
| CSA MMF | 13 | 6 | 3 | 2 | |
| CSA MTX | 11 | 10 | 6 | 4 | 4 |
| GVHD score skin | (modified Glucksberg criteria35 ) | (NIH consensus criteria3 ) | (NIH consensus criteria3 ) | ||
| Score 1 | 6 | 4 | |||
| Score 2 | 7 | 7 | 1 | ||
| Score 3 | 12 | 6 | 6 | ||
| GVHD overall grade | (modified Glucksberg criteria35 ) | (NIH consensus criteria3 ) | (NIH consensus criteria3 ) | ||
| Grade 1 | 10 | ||||
| Grade 2 | 10 | ||||
| Grade 3 | 2 | ||||
| Grade 4 | 3 | ||||
| Mild | 2 | ||||
| Moderate | 9 | 1 | |||
| Severe | 6 | 6 | |||
| Onset type of cGVHD | |||||
| DN | 4 | 2 | |||
| QUIESC | 9 | 5 | |||
| PROG | 4 | ||||
ALL, acute lymphoid leukemia; AML, acute myeloid leukemia; BM, bone marrow; CLL, chronic lymphoid leukemia; CML, chronic myeloid leukemia; CP, chronic phase; CR1/CR2/CR3/CR4/CR5, first/second/third/fourth/fifth complete remission; CSA, cyclosporin A; DN, de novo; F, female; HL, Hodgkin lymphoma; M, male; MAC, myeloablative conditioning; MDS, myelodysplastic syndrome; MMF, mycophenolate mofetil; MMUD, mismatched unrelated donor; MTX, methotrexate; MUD, matched unrelated donor; N/A, not available; NHL, non-Hodgkin lymphoma; PBSC, peripheral blood stem cell; PNH, paroxysmal nocturnal hemoglobinuria; PROG, progressive; QUIESC, quiescent; REFR, refractory; RIC, reduced intensity conditioning; sAML, secondary AML; SIB, sibling; TBI, total body irradiation.